Search

Displaying results 1321 - 1330 of 10000 in total
  1. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … In addition, nirsevimab was developed as a single-dose treatment for all infants experiencing their first RSV season, whereas palivizumab requires five monthly doses to cover an RSV season.

    Categories: Respiratory Syncytial Virus Anti-F Protein Monoclonal AntibodySynonyms: Immunoglobulin g1-kappa, anti-(human respiratory syncytial virus fusion glycoprotein f0 (protein f))human monoclonal antibody.gamma.1 heavy chain (1-456) (human vh (homo sapiens ighv1-69*01(ighd)-ighj4, *01 (90.1%)) (8.8.19) (1-126) -homo sapiens ighg1*03
  2. Target

    ATPase GET3

    go.drugbank.com/bio_entities/BE0000750
    TargetHumans

    ATPase required for the post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum (PubMed:17382883). Recognizes and selectively binds the transmembrane domain of TA proteins in the cytosol. This complex then...

    Synonyms: hARSA-I, hASNA-I
  3. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. … Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].

  4. Drug

    Remdesivir

    go.drugbank.com/drugs/DB14761
    ApprovedInvestigational

    Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. … and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal.

    Categories: MATE 1 Inhibitors, P-glycoprotein substratesProducts: VEKLURY® LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIAL, VEKLURY 100 MG İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇİN TOZ, 1 ADET
  5. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    years and older with a body weight of at least 40 kg. … [L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379]

  6. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels. … [L10403] It was developed by Global Blood Therapeutics, Inc.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  7. Indication

    Congenital Adrenal Hyperplasia (CAH)

    go.drugbank.com/conditions/DBCOND0033416
    Drugs: Betamethasone · Bupivacaine · Cortisone acetate · Crinecerfont · Dexamethasone · Hydrocortisone +7 more
    Synonyms: CAH - Congenital Adrenal Hyperplasia, Congenital Adrenal Hyperplasia (CAH)
  8. Indication

    Coronary Artery Disease (CAD)

    go.drugbank.com/conditions/DBCOND0032937
    Drugs: Amlodipine · Atorvastatin · Gemfibrozil
    Synonyms: CAD, Coronary Artery Disease (CAD)
  9. Drug

    Vibrio cholerae CVD 103-HgR strain live antigen

    go.drugbank.com/drugs/DB14443
    ApprovedInvestigational

    [A244494] Vaxchora was later approved by the European Commission in April 2020.[L39729] It is indicated for individuals aged two years and older.[L12801] … [L12801] Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria.

  10. Drug

    Carisoprodol

    go.drugbank.com/drugs/DB00395
    Approved

    This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine [FDA label, F4060, F4069]. … In January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse [A176062, A176077] despite having a low potential

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesSynonyms: N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate, (1-methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester